BioWorld

Sep. 22, 2009

Nektar Coffers Brimming with Cash Thanks to $1.5B Deal

Nektar Therapeutics Inc. will end the year flush with cash, after entering a deal valued at $1.5 billion with AstraZeneca plc. to develop a late-stage bowel drug candidate and a preclinical pain product. (BioWorld Today) Read More

Icagen, Pfizer Extend Deal; $1B in Milestones Still up for Grabs

BioCryst Gets More U.S. Funds for Peramivir, But Small Order

Good to the Bone: Denosumab Shines Again in Phase III Data

Analyst: Facet Investors Won't Bite on Biogen's Hostile Offer

1 H1N1 Shot Enough for Older Kids, But 2 Needed for Youngest

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...